ubiquinone and Dyspepsia

ubiquinone has been researched along with Dyspepsia* in 2 studies

Trials

2 trial(s) available for ubiquinone and Dyspepsia

ArticleYear
Effect of an extra-virgin olive oil enriched with probiotics or antioxidants on functional dyspepsia: a pilot study.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:15

    While antioxidants and probiotics have been proposed for the treatment of functional dyspepsia, current data are still heterogeneous and studies are poorly designed. Extra-virgin olive oil, a common ingredient of Mediterranean diet, has shown antioxidant properties.. To evaluate the effect of extra-virgin olive oil enriched with antioxidants or probiotics on functional dyspepsia.. This study has been designed as a "proof of concept". Extra-virgin olive oil enriched with antioxidants or probiotics was blindly added to the common diet of 8 subjects with functional dyspepsia for 7 days. Dyspeptic symptoms were then evaluated in all patients.. A significant improvement of dyspeptic symptoms was observed in subjects receiving the antioxidant or probiotic enriched oil diet, with a greater effect observed for the latter. Larger studies are now needed to confirm these data.

    Topics: Antioxidants; Carotenoids; Diet; Dietary Fats, Unsaturated; Dyspepsia; Humans; Lacticaseibacillus rhamnosus; Limosilactobacillus reuteri; Lycopene; Olive Oil; Pilot Projects; Plant Oils; Probiotics; Resveratrol; Saccharomyces; Selenium; Stilbenes; Ubiquinone

2013
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
    Experimental neurology, 2004, Volume: 188, Issue:2

    The safety and tolerability of high dosages of coenzyme Q10 were studied in 17 patients with Parkinson's disease (PD) in an open label study. The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day. The plasma level of coenzyme Q10 was measured at each dosage. Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage. Our data suggest that in future studies of coenzyme Q10 in PD, a dosage of 2400 mg/day (with vitamin E/alpha-tocopherol 1200 IU/day) is an appropriate highest dosage to be studied.

    Topics: Calcium; Coenzymes; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Female; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Pilot Projects; Safety; Time Factors; Ubiquinone; Vitamin E

2004